European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta ThalassemiaBusiness Wire • 02/13/24
Vertex Pharmaceuticals Stock Is Approaching a Huge Catalyst, But Is It a Buy?The Motley Fool • 02/08/24
Vertex Pharmaceuticals Has a $10 Billion Opportunity on the Table. Here's How You Can InvestThe Motley Fool • 02/06/24
Vertex Pharmaceuticals (VRTX) Q4 Earnings and Revenues Top EstimatesZacks Investment Research • 02/05/24
Vertex's Next-Gen Cystic Fibrosis Drug Scores Big; Shares Rise On Quarterly BeatInvestors Business Daily • 02/05/24
Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic FibrosisBusiness Wire • 02/05/24
Vertex Pharmaceuticals May Be About to Solve a Common Health Problem. Is the Stock a Buy?The Motley Fool • 02/02/24